Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.
Dakin, L.A., Block, M.H., Chen, H., Code, E., Dowling, J.E., Feng, X., Ferguson, A.D., Green, I., Hird, A.W., Howard, T., Keeton, E.K., Lamb, M.L., Lyne, P.D., Pollard, H., Read, J., Wu, A.J., Zhang, T., Zheng, X.(2012) Bioorg Med Chem Lett 22: 4599-4604
- PubMed: 22727640 
- DOI: https://doi.org/10.1016/j.bmcl.2012.05.098
- Primary Citation of Related Structures:  
4DTK - PubMed Abstract: 
Novel substituted benzylidene-1,3-thiazolidine-2,4-diones (TZDs) have been identified as potent and highly selective inhibitors of the PIM kinases. The synthesis and SAR of these compounds are described, along with X-ray crystallographic, anti-proliferative, and selectivity data.
Organizational Affiliation: 
Oncology iMed Sciences Group, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.